Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers - Wikidata - awgldk - TriplyDB

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers

http://www.wikidata.org/entity/Q28262260

about

The emerging role of miR-506 in cancer MicroRNAs, DNA Damage Response, and Cancer Treatment miR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axis MicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications.Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair.Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer Targeting and Regulating of an Oncogene via Nanovector Delivery of MicroRNA using Patient-Derived Xenografts.Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.The expression profile and prognostic value of APE/Ref-1 and NPM1 in high-grade serous ovarian adenocarcinoma.Current status on microRNAs as biomarkers for ovarian cancer.The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.MicroRNAs in gynecological cancers: Small molecules with big implications.MicroRNA-mediated drug resistance in ovarian cancer.Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma.Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.A miRNA signature assessing ovarian cancer prognosis.ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy.microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway.The long noncoding RNA-ROR promotes the resistance of radiotherapy for human colorectal cancer cells by targeting the p53/miR-145 pathway.MiR-143-3p suppresses the progression of ovarian cancer.The Network of Non-coding RNAs in Cancer Drug Resistance hsa‑miR‑24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c‑Myc/epithelial‑mesenchymal transition axis LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression

P2860

Q26740283-8DACEF17-6EFA-4430-B693-4E0AC7856040 Q28067062-0BFB52DC-C1AA-48B8-A5C2-865B52F1999A Q28267333-82BCFBE8-4322-4588-B0C6-B5FE4AC6D8E1 Q30244282-CB7F2444-FC5F-48CE-86E3-1971E2A0648B Q31138109-5513C8D5-042D-4BA4-882E-E914828AF55C Q33618910-D1D07BC3-08A2-4580-8D86-94EC39C7DDC1 Q36515439-D8F5C92C-1C9E-46A3-9F71-DEC7FF2D6F4D Q37046504-0FA1A15F-6502-4AEE-A0CB-581225BF2C0F Q37140001-27D83EFF-4AB4-441A-AA8A-72C4D5B5B40D Q37580300-05A78398-397B-4E1B-9686-F36F68EFEED2 Q37668563-CC80762A-2B5E-46E7-954D-F9460EC7A943 Q37736667-A8B0E4B9-E7EA-4B13-87EF-8E674F800E1D Q38546133-E8390C3F-EFCD-4A1E-8C07-407EADDFDF50 Q38633144-CD2A353D-3932-4EB2-AA50-384FF5CC6A85 Q38647236-60645B0F-D92F-46C4-8EDF-C6557114A108 Q38711390-19949652-4A1B-4711-ABCC-41190AD32647 Q38719535-DFCB8EED-12E4-4806-933E-E62E2FC79BC1 Q38975570-4E8F84E7-1F3A-4F0A-A078-E6B3A5B55583 Q39333266-09F33E6D-0EA2-4AC7-A678-CF0D1232046F Q39382756-1A9B9494-136D-4A92-BC7E-F16609CFD795 Q39391417-854C942A-21E3-44CA-93F5-F9D925C77B06 Q40555030-61F6B79B-57A1-43B0-A9EC-256A6C3F2460 Q42215256-7B6AB6DA-4FD8-47FC-81F6-93B475BE0E9F Q42317503-7D03475E-741E-4B33-8751-8E4206E38B10 Q42330446-A5F5C9AC-BB5D-4B7D-8AD0-6849CF699D7E Q47135713-56740ACD-0AB6-4550-A4D1-5F8D7F43D0AE Q47375547-35279A19-7CCB-4752-B3CE-ADC546026A0C Q47652779-D636D89B-5E85-4CB2-95C2-66ECE4D010A9 Q48219033-D53AA13E-2893-4645-87CA-2FCB60142162 Q48534871-39222E01-FD3F-465E-9315-6EF1B4FCFC88 Q48857817-FA00B742-0FE4-4E5D-BD84-2FF6730E9ECB Q49017323-7170EE11-21B5-413D-B249-C912CC63C706 Q52595106-2AC13838-84A5-4DC9-94D8-DFD0813C0981 Q58694197-015B3327-03C1-4A50-A35D-03EF5FB111D3 Q58758617-653FBA25-BAC6-4FDD-9DAE-1E02A55CAB0A Q58788537-2E13801A-673B-4DE6-9E10-09A1DCB8757E

P2860

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers

http://www.wikidata.org/entity/Q28262260

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@ast

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@en

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@nl

type

label

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@ast

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@en

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@nl

prefLabel

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@ast

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@en

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@nl

P1433

Q28262260-0EEA41E3-C3C4-4F73-9ABC-F5F7A5E826A7

P1476

Q28262260-A8A1F25F-6C91-44E8-A228-FA0E2C9DAA1B

P2093

Q28262260-203D9AD5-3343-437A-BF63-59C5AB284218

Q28262260-2E9D2C1C-DC64-4911-B021-C574334BDED7

Q28262260-4038F414-3BFC-45C4-ACBB-2F7A267124CD

Q28262260-512FCB2B-AF3E-4138-A17C-2F5A6184710F

Q28262260-55F9028E-C515-47AE-BBA9-F76E90607531

Q28262260-5B04BF75-54DE-4387-8F37-B23C6510336C

Q28262260-5B500B34-08D0-4424-B286-010B3B10E016

Q28262260-5BB38771-FFD4-4D60-B6F7-50A022CE275F

Q28262260-70204A39-9427-4E35-98D4-4FB6389BCBBB

Q28262260-7A8D6AFA-58C5-4665-AA40-B4734FC8BF03

P2860

Q28262260-03A7B61E-A8E4-4D3B-9261-8BB8B3192437

Q28262260-191C1654-3976-46C5-95F1-3A9BC5680BC0

Q28262260-1F4FD372-03D2-4580-91B8-9155AF145957

Q28262260-2C100EFB-6768-4DED-924A-B15A926D6E1B

Q28262260-2E637461-E59A-457E-8673-E794B9A9EE9C

Q28262260-3371BE2F-F1FF-4A11-9F0B-8853F4B48872

Q28262260-36809745-5D9F-4EE8-B30D-B8AF1C131AFE

Q28262260-417FD651-578B-423B-A65F-80B52AEC6B3C

Q28262260-4B77FC51-FBE0-4A79-B8A7-8372123DC5F2

Q28262260-4ED55F61-DB7B-4413-8244-9AC7702B75DD

P304

Q28262260-067A7736-4E02-405B-BEEB-2C097A354C50

P31

Q28262260-31642CCA-CFBD-43BF-9420-DC73C9ECCAEE

P3181

Q28262260-0259156C-CB68-43F9-9854-4454CDA39052

P356

Q28262260-99B48910-A36D-4C27-AA2B-E5D8A1F6841D

P407

Q28262260-695C4FAA-9DC0-47B6-9A0D-8684E98DDC06

P433

Q28262260-BF880E56-82C1-4F18-9995-0B44804A9037

P478

Q28262260-CB2B3221-F619-4A4D-AE48-73747EC19BC8

P50

Q28262260-2233B3F2-15E8-4E1E-AC5A-A1CF0977D5B5

Q28262260-53C7CB8F-A5F9-47C4-AFB0-1A5944E124A4

Q28262260-A6459F35-A0AB-4BDD-B12E-8F285688F42C

Q28262260-B1668838-DA04-49BB-AED4-22B3A9415280

Q28262260-F9B8839A-91D6-420D-AC15-ED3739FA5B22

P577

Q28262260-09BD2E0C-56D4-4C81-9189-7BDB69CACADB

P5875

Q28262260-B0D19E26-D3A4-4B48-BB8A-244DFBEA4381

P698

Q28262260-7F13DE21-CFC9-4BAF-9106-53B527B2377C

P921

Q28262260-36C0D97E-BE26-4A76-82D1-F03DAAC1114C

Q28262260-3DEA8F7F-7494-4EBD-B566-5814CC511897

Q28262260-A04811D9-9C7E-4B94-A358-D3F5089AC777

P932

Q28262260-60A1930F-DA8C-4BA4-90D7-5953C0AD20E1

P3181

P356

P1433

Journal of the National Cancer Institute

P1476

Augmentation of response to ch ...... AD51 in serous ovarian cancers

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Chad V Pecot

http://www.w3.org/2001/XMLSchema#string

David Cogdell

http://www.w3.org/2001/XMLSchema#string

Fengxia Xue

http://www.w3.org/2001/XMLSchema#string

Gabriel Lopez-Berestein

http://www.w3.org/2001/XMLSchema#string

Guoyan Liu

http://www.w3.org/2001/XMLSchema#string

Kexin Chen

http://www.w3.org/2001/XMLSchema#string

Limei Hu

http://www.w3.org/2001/XMLSchema#string

Lingegowda S Mangala

http://www.w3.org/2001/XMLSchema#string

Ping Ji

http://www.w3.org/2001/XMLSchema#string

P2860

Purified human BRCA2 stimulates RAD51-mediated recombination

Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells

Suppression of non-small cell lung tumor development by the let-7 microRNA family

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Integrated genomic analyses of ovarian carcinoma

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

P304

djv108-djv108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4628362

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/JNCI/DJV108

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Delia Mezzanzanica

Cristian Rodriguez-Aguayo

Ilya Shmulevich

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277082832

http://www.w3.org/2001/XMLSchema#string

P698

25995442

http://www.w3.org/2001/XMLSchema#string

P921

P932

4554255

http://www.w3.org/2001/XMLSchema#string